Scholarlink

<p>Hepatocellular carcinoma (HCC) is a metabolically active malignancy. Cuproptosis, a copper-dependent programmed cell death pathway, has been found to be closely associated with tumor progression. Cells with strong oxidative phosphorylation (OXPHOS) capacity exhibit heightened susceptibility to cuproptosis. We demonstrate that the tumor suppressor ASPP2 regulates the key cuproptosis modulator FDX1 by promoting NR2F2 recruitment to the FDX1 promoter in HCC. ASPP2 promotes intracellular copper accumulation through lipoylated protein oligomerization, thereby inducing cuproptosis. Furthermore, ASPP2 facilitates mitochondrial OXPHOS via enhanced tricarboxylic acid (TCA) cycle activity, which sensitizes HCC cells to cuproptosis. In vitro and in vivo experiments confirmed that ASPP2 overexpression suppresses tumor growth and synergizes with copper ionophores. Clinical specimen analysis revealed ASPP2–FDX1 co-expression in 90 HCC cases. A prognostic model incorporating ASPP2 and cuproptosis-related genes demonstrates superior survival prediction in TCGA cohorts. These findings establish the ASPP2–FDX1–NR2F2 axis as a metabolic-cuproptosis link and propose a novel therapeutic strategy for HCC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

ASPP2 inhibits hepatocellular carcinoma growth by regulating cuproptosis via mitochondrial protein lipoylation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月24日

查看全文
  • Lu Yang,
  • Xuhui Li,
  • Yutong Jiang,
  • Mingzhu Zhang,
  • Tiantian Wu,
  • Peixian Pi,
  • Zhuozhuo Han,
  • Zhiyu Zhang,
  • Fangyuan Kong,
  • Xiuhong Lu,
  • Hao Yang,
  • Chaohui Zuo,
  • Gang Huang,
  • Jian Zhao,
  • Beibei Liang

摘要

Hepatocellular carcinoma (HCC) is a metabolically active malignancy. Cuproptosis, a copper-dependent programmed cell death pathway, has been found to be closely associated with tumor progression. Cells with strong oxidative phosphorylation (OXPHOS) capacity exhibit heightened susceptibility to cuproptosis. We demonstrate that the tumor suppressor ASPP2 regulates the key cuproptosis modulator FDX1 by promoting NR2F2 recruitment to the FDX1 promoter in HCC. ASPP2 promotes intracellular copper accumulation through lipoylated protein oligomerization, thereby inducing cuproptosis. Furthermore, ASPP2 facilitates mitochondrial OXPHOS via enhanced tricarboxylic acid (TCA) cycle activity, which sensitizes HCC cells to cuproptosis. In vitro and in vivo experiments confirmed that ASPP2 overexpression suppresses tumor growth and synergizes with copper ionophores. Clinical specimen analysis revealed ASPP2–FDX1 co-expression in 90 HCC cases. A prognostic model incorporating ASPP2 and cuproptosis-related genes demonstrates superior survival prediction in TCGA cohorts. These findings establish the ASPP2–FDX1–NR2F2 axis as a metabolic-cuproptosis link and propose a novel therapeutic strategy for HCC.